Company news
Kura Oncology, Inc. news in 2020
Kura Oncology, Inc.'s news releases, calls and decks from 2020, newest first.
Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
December 10, 2020
Kura Oncology to Participate in the JMP Securities Hematology Summit
December 9, 2020
Kura Oncology Announces Pricing of $300 Million Public Offering of Common Stock
December 7, 2020
Kura Oncology Announces Commencement of Public Offering of Common Stock
December 6, 2020
Kura Oncology Presents First Clinical Data for Menin Inhibitor KO-539 at American Society of Hematology Annual Meeting
December 4, 2020
Kura Oncology to Host Virtual Investor Event on December 5, 2020
November 23, 2020
Kura Oncology Reports Third Quarter 2020 Financial Results
November 4, 2020
Kura Oncology to Report Third Quarter 2020 Financial Results
October 28, 2020
Kura Oncology Reports Preclinical Results Showing Antitumor Activity of Tipifarnib in Combination with PI3Kα Inhibitor in Head and Neck Squamous Cell Carcinoma
October 25, 2020
Kura Oncology Announces Preliminary Data for Menin Inhibitor KO-539 Accepted for Oral Presentation at ASH
October 6, 2020
Kura Oncology Appoints Dr. Stephen Dale as Chief Medical Officer
August 24, 2020
Kura Oncology Reports Second Quarter 2020 Financial Results
August 5, 2020
Kura Oncology to Present at Wedbush PacGrow Healthcare Virtual Conference
August 3, 2020
Kura Oncology to Report Second Quarter 2020 Financial Results
July 29, 2020
Kura Oncology to Participate in JMP Securities Hematology & Oncology Forum
June 10, 2020
Kura Oncology Reports Overall Survival Data from Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinoma
May 28, 2020
Kura Oncology Announces Three Abstracts Accepted for Presentation at ASCO20 Virtual Scientific Program
May 12, 2020
Kura Oncology to Present at BofA Securities Virtual Health Care Conference 2020
May 6, 2020
Kura Oncology Announces Pricing of $125 Million Public Offering of Common Stock
May 5, 2020
Kura Oncology Reports First Quarter 2020 Financial Results
May 3, 2020
Kura Oncology to Report First Quarter 2020 Financial Results
April 28, 2020
Kura Oncology Receives Fast Track Designation for Tipifarnib in T-Cell Lymphomas
March 2, 2020
Kura Oncology Reports Fourth Quarter and Full Year 2019 Financial Results
February 24, 2020
Kura Oncology Announces Transition of Chief Medical Officer
January 22, 2020
Kura Oncology Appoints Kirsten Flowers as Chief Commercial Officer
January 5, 2020
Decks in 2020
- Investor Presentation (December 2020)
Investor deck · 34 slides · Dec 7, 2020
- Technical Presentation (November 2020)
Technical · 12 slides · November 2020
- J.P. Morgan Healthcare Conference 2020
Conference · 27 slides · Jan 13, 2020
- ASCO 2020
Conference · 17 slides · 2020